The 5000% case: a glimpse into the financial issue of lung cancer treatment-Reference-Cited by-同舟云学术

The 5000% case: a glimpse into the financial issue of lung cancer treatment

Published:2016-04-30 Issue:5 Volume:47 Page:1331-1333
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Remon Jordi,Bonastre Julia,Besse Benjamin

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. Center for Global Development. The 5000% price increase and the economic case for pharma price regulation. www.cgdev.org/blog/5000-price-increase-and-economic-case-pharma-price-regulation Date last updated: September 23, 2015. Date last accessed: March 14, 2016.

2. The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience

3. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

4. Barlesi F , Mazieres J , Merlio J-P , et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; [in press DOI: 10.1016/S0140-6736(16)00004-0].

5. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Out‐of‐pocket spending of deceased cancer patients in five European countries and Israel;European Journal of Cancer Care;2020-11-15

2. Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study;BMC Cancer;2018-10-22